High Rates of Obesity and Non-Communicable Diseases Predicted across Latin America

National Heart Forum, London, England.
PLoS ONE (Impact Factor: 3.53). 08/2012; 7(8):e39589. DOI: 10.1371/journal.pone.0039589
Source: PubMed

ABSTRACT Non-communicable diseases (NCDs) such as cardiovascular disease and stroke are a major public health concern across Latin America. A key modifiable risk factor for NCDs is overweight and obesity highlighting the need for policy to reduce prevalence rates and ameliorate rising levels of NCDs. A cross-sectional regression analysis was used to project BMI and related disease trends to 2050. We tested the extent to which interventions that decrease body mass index (BMI) have an effect upon the number of incidence cases avoided for each disease. Without intervention obesity trends will continue to rise across much of Latin America. Effective interventions are necessary if rates of obesity and related diseases are to be reduced.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overnutrition may lead to obesity. Maternal obesity may affect fertility not only via anovulation, but also through direct effects on oocytes and preimplantation embryos, indicating that the periconceptional period is sensitive to conditions of overnutrition. The periconceptional period includes from folliculogenesis to implantation. Animal model studies suggest that oocytes derived from obese females usually have a small size and mitochondrial abnormalities. These disruptions are probably induced by changes in the components of the ovarian follicular fluid. Experimental evidence also suggests that obesity may affect the microenvironment in oviducts and uterus, resulting in development of preimplantation embryos with reduced cell numbers and up-regulation of proinflammatory genes. However, further research is needed for in-depth characterization of the effects of maternal obesity during the periconceptional period.
    Endocrinología y Nutrición 02/2015; DOI:10.1016/j.endonu.2015.01.004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 40(4) DEBATE ( RESUMEN Embelleciendo la vida se puede alcanzar una tercera edad enriquecedora, edificante y larga. El "adaptismo" es una corriente explicativa de la nutrición y alimentación humana que pretende matizar la vergüenza de la existencia de malnutrición en el siglo xxi con pinceladas lingüísticas tranquilizantes para sus generadores. Las actuales generaciones son el resultado de alternos períodos de hambrunas y plétora, los cuales seleccionaron a los sobrevivientes. Según la hipótesis de la "Programación Fetal" o del "Fenotipo Ahorrador" ABSTRACT Making life beautiful is a way of reaching a long, enriching and fruitful older age. "Adaptism" is an explanatory current of human nutrition and feeding that intends to attenuate the shameful existence of malnutrition in the 21st century with reassuring linguistic phrases for its generators. Today's generations are the result of alternative periods of famine and plethora which selected the survivors. According to the "Fetal Programming "or "Saving Phenotype" hypothesis, diseases at adulthood is programmed by hormones and neurotransmitters during the critical periods of fetal development. This hypothesis becomes the center of debates on the alarming epidemiological behavior of diabetes, obesity and cancer at present. Extension of life expectancy, as a result of a very successful combination of well-preserved system, good capacity to face stress, adequate life style and genetic load, is accompanied by the prevention of non-communicable diseases. The actions to attain this goal should begin before the intrauterine life of the fetus. Aging as such is not an unsolved issue; the problem lies in marginalization, disease and poverty that do not allow the elderly to have a decent life in many regions of the world.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The number of individuals diagnosed with type 2 diabetes mellitus is expected to rise disproportionately in Hispanic/Latino populations. We therefore aimed to assess the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin specifically in Hispanic/Latino patients with type 2 diabetes mellitus. Data from 745 patients who self-identified their ethnicity as Hispanic or Latino were pooled from six randomized, placebo-controlled phase 3 trials. Participants received linagliptin (5 mg/day) or placebo as monotherapy, or in combination with other oral antidiabetes drugs for 18 or 24 weeks. The placebo-adjusted mean change (95% CI) in glycated hemoglobin from baseline (mean 8.2%) was -0.63% (-0.77 to -0.48; p<0.0001) at week 18, and -0.58% (-0.74 to -0.42; p<0.0001) at week 24. The placebo-adjusted mean change (95% CI) in fasting plasma glucose from baseline was -11.7 mg/dL (-19.3 to -4.0; p=0.0028) at week 18 and -14.1 mg/dL (-22.0 to -6.3; p=0.0004) at week 24. Hypoglycemia incidence was 17.4% with linagliptin and 21% with placebo. In patients not receiving concomitant sulfonylurea, the hypoglycemia incidence was 10.1% with linagliptin and 19.4% with placebo. The overall incidence of adverse events (AEs), drug-related AEs, and serious AEs with linagliptin was similar to placebo (AEs 67.6% vs 68.9%; drug-related AEs 15.1% vs 18.7%; serious AEs 3.6% vs 3.0%). The mean body weight remained unchanged in both groups. In Hispanic/Latino patients with inadequately controlled type 2 diabetes mellitus, linagliptin provided clinically meaningful improvements in glycemic control without weight gain or increased risk of hypoglycemia.
    04/2014; 2(1):e000020. DOI:10.1136/bmjdrc-2014-000020

Full-text (3 Sources)

Available from
May 29, 2014